Clinical Trials Logo

Clinical Trial Summary

Participants aged 18 to 75 years with severe hepatic impairment (Child-Pugh class C) who meet the full study eligibility criteria will be enrolled into the study. For each participant with severe hepatic impairment, a corresponding healthy participant will be enrolled who matches with regard to age, sex, BMI, and, if possible, smoking habit. A single dose of 55-mg EQ143 tablet will be administered in the morning on Day 1, and participants will remain for 5 days (4 nights) in the study center for collection of blood samples and safety monitoring. Participants will attend outpatient follow-up visits on Days 5, 6, 8, and 9 for additional blood sampling and safety assessments. The study will measure and describe the concentrations of EQ143 and its metabolite (HAS-719) in blood plasma over the course of 9 days (including calculation of PK parameters), the degree of EQ143 binding to plasma proteins in blood, and the safety of administering a single dose of EQ143 in severely hepatically impaired and matched healthy participants.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05199610
Study type Interventional
Source EQRx International, Inc.
Contact Dannielle Hall
Email [email protected]
Status Recruiting
Phase Phase 1
Start date March 2022
Completion date December 2022

See also
  Status Clinical Trial Phase
Completed NCT03664544 - PK Study in Subjects With Severe Hepatic Impairment Phase 1
Completed NCT05116826 - Nitazoxanide Pharmacokinetic Parameters in Hepatic Impaired Patients Phase 1
Completed NCT02170220 - Pharmacokinetics, Safety and Tolerability of Vortioxetine in Normal Hepatic Function or Severe Hepatic Impairment Phase 1
Recruiting NCT03818672 - Steady-State Pharmacokinetics of Rifaximin 550 mg Tablets in Healthy and Hepatically Impaired Subjects Phase 4
Completed NCT02138162 - A Study to Investigate the Effect of Severely Diminished Liver Function on the Metabolism, Safety, and Tolerability of a Single Oral Dose of Enzalutamide in Men Phase 1
Completed NCT03865446 - Evaluate Severe Hepatic Impairment on Dacomitinib PK Phase 1
Not yet recruiting NCT05224609 - Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics and Safety of Lorlatinib Phase 1